The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R.sub.1 is selected from the group consisting of —OH, ═O(carbonyl), H, and C.sub.1-C.sub.3 alkyl; R.sub.2 is selected from the group consisting of —OH, H, and C.sub.1-C.sub.3 alkyl; R.sub.3 is selected from the group consisting of —OH, ═O, H, and C.sub.1-C.sub.3 alkyl; R.sub.4 is selected from the group consisting of —OH, H, and C.sub.1-C.sub.3 alkyl; and none, one, two, three or four of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

##STR00001##

The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R.sub.1 is selected from the group consisting of —OH, ═O(carbonyl), H, and C.sub.1-C.sub.3 alkyl; R.sub.2 is selected from the group consisting of —OH, H, and C.sub.1-C.sub.3 alkyl; R.sub.3 is selected from the group consisting of —OH, ═O, H, and C.sub.1-C.sub.3 alkyl; R.sub.4 is selected from the group consisting of —OH, H, and C.sub.1-C.sub.3 alkyl; and none, one, two, three or four of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.

##STR00001##

A composition including a Moringa plant component for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of cancer in a subject is provided. The composition may comprise a Moringa plant component in an amount of 1 mg to 1750 mg, and sulforaphane or a sulforaphane derivative in an amount of 1 mg to 50 mg. Alternatively, the composition may comprise a Moringa plant component in an amount of 150 mg to 1500 mg sulforaphane precursor in an amount of 1 mg to 50 mg. The Moringa plant component can be Moringa leaf extract containing 10 mg of moringin per 1000 mg of the Moringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.

A composition including a Moringa plant component for treating, preventing, reducing the occurrence of, decreasing the symptoms associated with, and/or reducing secondary recurrences of cancer in a subject is provided. The composition may comprise a Moringa plant component in an amount of 1 mg to 1750 mg, and sulforaphane or a sulforaphane derivative in an amount of 1 mg to 50 mg. Alternatively, the composition may comprise a Moringa plant component in an amount of 150 mg to 1500 mg sulforaphane precursor in an amount of 1 mg to 50 mg. The Moringa plant component can be Moringa leaf extract containing 10 mg of moringin per 1000 mg of the Moringa leaf extract. The composition may also include at least one of a mushroom extract or powder and a broccoli extract or powder.

Provided is a fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae and its use. The fermentation fungal substance is obtained by solid fermentation with Astragalus membranaceus powder as a fermentation substrate and Paecilomyces cicadae as a fermentation strain. The fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae in the present disclosure plays a significant role in treating hyperuricemia and/or hypertriglyceridemia.

Provided is a fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae and its use. The fermentation fungal substance is obtained by solid fermentation with Astragalus membranaceus powder as a fermentation substrate and Paecilomyces cicadae as a fermentation strain. The fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae in the present disclosure plays a significant role in treating hyperuricemia and/or hypertriglyceridemia.

The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace that has been co-fermented with a complex fungi, compounded as a tablet or formulated within a capsule. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of at least one part soluble dietary fiber to 30 parts insoluble dietary fiber, and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

The present invention is a cannabidiol oral dosage form including predominantly or exclusively hemp pomace that has been co-fermented with a complex fungi, compounded as a tablet or formulated within a capsule. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of at least one part soluble dietary fiber to 30 parts insoluble dietary fiber, and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).

Described herein are fungal compound compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect, the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof, optionally combined with one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum), or combinations thereof, optionally one or more adversive compounds, optionally one or more monoamine oxidase inhibitor (MAOI) compounds, and optionally one or more pharmaceutically acceptable excipients.

Described herein are fungal compound compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect, the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof, optionally combined with one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum), or combinations thereof, optionally one or more adversive compounds, optionally one or more monoamine oxidase inhibitor (MAOI) compounds, and optionally one or more pharmaceutically acceptable excipients.